Moderna's Covid-19 vaccine sales to trail Pfizer's total significantly in 2021 and 2022
Pfizer’s and Moderna’s mRNA vaccines to prevent Covid-19 are often considered equals in many respects. Both have shown strong protection from the virus, with limited side effects or safety concerns among the hundreds of millions who have now received them.
But in its second quarter earnings call Thursday, Moderna revealed how the two are diverging when it comes to vaccine sales, as Moderna’s expectations for 2021 total about $20 billion, based on the expected manufacture of between 800 million and 1 billion doses. Pfizer said last week it expects about $33 billion in 2021 Covid vaccine sales on 2.1 billion doses, although that amount may increase to about 3 billion doses.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
